$NVS News

Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts

Novartis Q2 2026 Earnings Call Transcript

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2

Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

ARGUS RESEARCH CORPORATION Upgrades Novartis AG - Depositary Receipt (NVS)

Novartis AG Receives Health Canada Approval For Vanrafia To Reduce Preoteinuria Production In Immunoglobulin A Nephropathy Patients

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push

Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments

Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal

Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment

Curium Prevails Patent Dispute Against Novartis Subsidiary Regarding Curium's Lutetium Lu 177 Dotatate Product; Court Claims Advanced Accelerator Applications' Claims Against Curium Invalid

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

Novartis Presents Published Phase III REPLENISH Data In New England Journal Of Medicine Showing Cosentyx Achieves Statistically Significant Sustained Remission And Steroid Sparing In Polymyalgia Rheumatica With No New Safety Signals

Novartis Announces Pluvicto's New Data From PSMAddition Shows Enhanced Prostate-Specific Antigen Responses; Risk Of Prostate-Specific Antigen Lowered By 58%

Novartis shares are trading lower after the company reported worse-than-expected Q1 financial results.

Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates

Novartis Reaffirms FY2026 Outlook; Net Sales to Grow Low Single-Digit, Core Operating Income to Decline Low Single-Digit